Topic Highlight
Copyright ©2013 Baishideng.
World J Virol. May 12, 2013; 2(2): 102-109
Published online May 12, 2013. doi: 10.5501/wjv.v2.i2.102
Table 1 Oncogenic viruses are latent/persistent viruses
VirusEBVHHV-8HPVHBVHCVHTLV-1
Associated tumor(s): viral protein(s) expressedBL: EBNA-1KS: vFLIP, vCYC, LANA-1Anogenital, oral, skin and laryngeal cancers: E6, E7HCC: HBxHCC: CP10, NS3, NS5ATL: tax
NPC, TCL: EBNA1 + LMP1PEL, MCD: vFLIP, vCYC, LANA-1, LANA-2, vIL-6
HL: EBNA1 + LMP1-2
PTLD: EBNA1-6 + LMP1-2
PersistencyAlwaysAlways20% infected subjects90%-95% infected newborns70%-85% infected subjectsAlways
5% infected adults
Period between infection and tumor onset10-20 yr10-20 yr5-20 yr10-30 yr10-30 yr20-30 yr
Table 2 Viral proteins inducing genetic damage
VirusEBVHHV-8HPVHBVHCVHTLV-1
Latent proteinsEBNA-1LANA-1[64]E6, E7[66,67]Naturally occurring pre-S mutants[68]--
EBNA-3Cv-CYC[65]
LMP-1[63]
Lytic proteinsBZLF-1[69]-E1, E2[71,72]HBx[73,74]CoreTax[76,77]
BGLF-5[70]NS3[23,62]
NS5[75]
Table 3 Virus products controlling cellular epigenetic modifications
VirusEBVHHV-8HPVHBVHCVHTLV-1
EBNA-3A, EBNA-3C[78]LANA-1[81]E6[83]HBx[85,86]Core[87]Tax[88]
LMP-1[79]microRNA[82]E7[84]
LMP-2[80]